Peripheral arterial disease (PAD) is characterised by atherosclerotic narrowing of the arteries supplying the limbs — most commonly the lower extremities. PAD affects approximately 8–10 million Americans, predominantly in individuals over 50 with risk factors including smoking, diabetes mellitus, hypertension, and hyperlipidaemia. The hallmark symptom of lower extremity PAD is intermittent claudication — reproducible, cramping pain in the calf, thigh, or buttock that occurs during walking and is relieved by rest within minutes. The pathophysiological basis is inadequate oxygen delivery to exercising muscle due to fixed arterial stenosis that cannot adequately increase flow with exercise demand.
The management of PAD and intermittent claudication is primarily vascular and lifestyle-based. The most evidence-based intervention for improving walking distance and quality of life in claudication is supervised exercise therapy (SET) — structured, supervised walking programmes that induce physiological adaptations (enhanced skeletal muscle metabolism, improved collateral vessel development, reduced free radical damage) that significantly outperform pharmacological interventions in head-to-head comparisons. Revascularisation (percutaneous angioplasty, stenting, or surgical bypass) is reserved for limb-threatening ischaemia (critical limb ischaemia — rest pain, non-healing ulcers, gangrene) or severe claudication inadequately managed by exercise and medical therapy. Cardiovascular risk factor management (antiplatelet therapy with aspirin or clopidogrel, statin therapy, blood pressure control, smoking cessation) is mandatory for all PAD patients, as PAD is a potent marker of systemic atherosclerotic burden and associated coronary and cerebrovascular risk.
The pharmacological options for symptomatic claudication are limited and only modestly effective relative to exercise therapy. Cilostazol (Pletal) — a phosphodiesterase-3 inhibitor — is the most effective approved agent (improves pain-free walking distance by approximately 40–60%), but is contraindicated in heart failure. Pentoxifylline (Trental) is a haemorrheologic agent with a more modest clinical benefit profile. Both have roles in patients unable to participate in supervised exercise therapy programmes.
Lucas Clinic provides detailed information about the blood flow medication in our inventory: